

Tae Oh Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5917246/publications.pdf>

Version: 2024-02-01

10
papers

147
citations

1478505

6
h-index

1281871

11
g-index

12
all docs

12
docs citations

12
times ranked

302
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID). <i>Intestinal Research</i> , 2015, 13, 193.	2.6	60
2	Nationwide validation study of diagnostic algorithms for inflammatory bowel disease in Korean National Health Insurance Service database. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 760-768.	2.8	32
3	Sexual Dysfunction and Fertility Problems in Men with Inflammatory Bowel Disease. <i>World Journal of Men's Health</i> , 2020, 38, 285.	3.3	25
4	Factors associated with low adherence to oral 5-aminosalicylic acid in patients with ulcerative colitis. <i>PLoS ONE</i> , 2019, 14, e0214129.	2.5	7
5	Clinical Efficacy of Probiotic Therapy on Bowel-Related Symptoms in Patients with Ulcerative Colitis during Endoscopic Remission: An Observational Study. <i>Gastroenterology Research and Practice</i> , 2022, 2022, 1-5.	1.5	7
6	Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study. <i>Gut and Liver</i> , 2022, 16, 764-774.	2.9	6
7	Clinical Features and Long-term Prognosis of Crohn's Disease in Korea: Results from the Prospective CONNECT Study. <i>Gut and Liver</i> , 2022, 16, 907-920.	2.9	4
8	Quality of Life in Newly Diagnosed Moderate-to-Severe Ulcerative Colitis: Changes in the MOSAIK Cohort Over 1 Year. <i>Gut and Liver</i> , 2021, , .	2.9	2
9	Subjective Needs and Thoughts for the Treatment of Patients with Inflammatory Bowel Disease: Applying Q Methodology. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2021, 78, 37-47.	0.4	1
10	A Randomized, Double-Blind, Active-Control, Noninferiority, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of Esomeprazole/Sodium Bicarbonate 20/800 mg in Patients with Nonerosive Gastroesophageal Reflux Disease. <i>Gut and Liver</i> , 2022, , .	2.9	1